Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies

The results of phase 2 randomized controlled trials for the prevention of episodic and chronic migraine demonstrating the efficacy and safety of four mAbs targeting the calcitonin gene-related peptide (CGRP) pathway [ALD403 (eptinezumab), AMG334 (erenumab), LY2951742 (galcanezumab) and TEV48125 (fre...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in neurology Vol. 30; no. 3; p. 272
Main Authors Mitsikostas, Dimos D, Reuter, Uwe
Format Journal Article
LanguageEnglish
Published England 01.06.2017
Online AccessGet more information

Cover

Be the first to leave a comment!
You must be logged in first